TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025 [Yahoo! Finance]
TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025
TriSalus Life Sciences (NASDAQ:TLSI) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
TriSalus Life Sciences (NASDAQ:TLSI) was upgraded by analysts at
Wall St
TriSalus Life Sciences (NASDAQ:TLSI) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.